欧洲药品管理局人用药品委员会(CHMP)在对丁咯地尔(buflomedil)口服制剂和注射剂进行有效性和安全性评估后,于2011年5月19日发布公告,建议在欧盟范围停止供应丁咯地尔口服制剂。丁咯地尔为α-肾上腺素受体阻断剂,通过扩张脑部和身体其他部位的末梢血管以增加缺氧组织的血流量,用于治疗外周动脉硬化闭塞性疾病(PAOD),如雷诺综合征、血栓闭塞性脉管炎、周围血管痉挛、间歇性跛行等;也用于治疗慢性脑血管供血 The European Medicines Agency’s Commission on Human Medicines (CHMP) issued a public announcement on May 19, 2011, after assessing the effectiveness and safety of buflomedil oral formulations and injections, recommending the cessation of supply in the EU Phenol oral preparation. Buflomedil is an alpha-adrenergic receptor blocker that increases blood flow to hypoxic tissues by dilating peripheral blood vessels in the brain and other parts of the body for the treatment of peripheral arteriosclerotic occlusive disease (PAOD) Syndrome, thromboangiitis obliterans, peripheral vasospasm, intermittent claudication, etc .; also used to treat chronic cerebrovascular blood supply